Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Sponsor: Arrowhead Pharmaceuticals
Terminated
Company decision to discontinue trial
Other terminated trials from Arrowhead Pharmaceuticals
Other Chronic Hepatitis B trials with similar outcome
A PHASE2 clinical study on Chronic Hepatitis B, this trial is terminated or withdrawn. The trial is conducted by Arrowhead Pharmaceuticals and has accumulated 10 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Dec 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Nov 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arrowhead Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .